Awardee OrganizationUNIV OF MASSACHUSETTS MED SCH WORCESTER
Description
Abstract Text
Summary
Immunological control of mucosal barrier development and maintenance is a critical process, as imbalances in
immune sentinel activity can lead to skin, lung and gut inflammatory diseases. Central in the mucosal tissue
homeostasis are type 3 cytokine producing lymphocytes. Cytokines, cytokines receptors and master
transcriptions involved in tissue development and barrier fortification have been identified based on analyses of
loss of function models in human and mice. However, non-inflammatory factors that orchestrate the type 3
responses in tissues to assure proper immune reactions and prevent aberrant inflammation have not been well
characterized.
We discovered that oxysterols, a major class of cholesterol metabolites with established immunomodulatory
activities, are the primary positional cues for the stereotypical type 3 lymphocytes in the skin called Tγδ17 cells.
Ebi2 (encoded by Gpr183) is the G protein coupled receptor (GPCR) that senses specific types of oxysterols,
and is expressed on all type 3 cytokine producing lymphocytes. Increased dietary cholesterol enhances Tgd17
activity at the skin interface via augmented oxysterol production and sensing. However, how tissue resident cells
contribute to the anatomical framework that generate the final positional cues for dermal IL-17 secreting innate
T lymphocytes is not known. Moreover, whether oxysterols are involved in the development of skin-tropic Tgd17
and other type 3 cytokine producing lymphocytes is not known.
In this project we will test the hypothesis that Tgd17 cells maintain barrier tissue homeostasis by sensing cues
that reflect nutritional states and inputs from the peripheral nerve system. Metabolic changes in the epithelial-
neuronal niche in the skin control optimal microanatomical Tgd17 positioning and function via GPR183. This
integrated sensory mechanism for cholesterol metabolism and neuronal inputs is imprinted early in Tγδ17
thymocyte maturation through interactions with a novel subset of thymic epithelial cells programmed to produce
oxysterols. The conceptual basis of this project is innovative as there are no precedents for the oxysterol-
regulated mucosal tissue hub integrating epithelial-neuronal-immune communications critical for barrier tissue
fitness.
Public Health Relevance Statement
Relevance
Excessive type 3 cytokine response is responsible for psoriasis and eczema, a skin disorder
involving impaired skin barrier integrity. Obesity, often driven by intake of high fat western diet, is
one of the non-genetic factors associated with morbidity and severity of these two chronic
inflammatory skin diseases. Despite major progress in understanding the immunological effect of
dietary lipids, little is known about the molecular mechanism linking high fat diet to tissue
inflammatory diseases. We have discovered that dietary cholesterol and its metabolites oxysterols
shapes innate T lymphocytes resident in the skin that are equipped with sensors of altered
oxysterol homeostasis. We will test the hypothesis that the fine specificity of skin positioning of
these dermal T cells guided by oxysterols produced in a specialized skin niche is obligatory for
proper immune reactions. Skin-homing innate T cells are imprinted to sense cholesterol
byproducts during their development in the thymus and we will seek to decipher the molecular
features controlling T cell-thymic niche crosstalk. This project will establish the functional
importance of tissue cholesterol metabolism to achieve mucosal tissue immune homeostasis and
provide new intervention strategies to treat inflammatory disorders in the skin, lung and gut.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
603847393
UEI
MQE2JHHJW9Q8
Project Start Date
01-November-2021
Project End Date
31-October-2026
Budget Start Date
01-November-2024
Budget End Date
31-October-2025
Project Funding Information for 2025
Total Funding
$686,599
Direct Costs
$409,910
Indirect Costs
$276,689
Year
Funding IC
FY Total Cost by IC
2025
National Institute of Allergy and Infectious Diseases
$686,599
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI158832-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI158832-04
Patents
No Patents information available for 5R01AI158832-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI158832-04
Clinical Studies
No Clinical Studies information available for 5R01AI158832-04
News and More
Related News Releases
No news release information available for 5R01AI158832-04
History
No Historical information available for 5R01AI158832-04
Similar Projects
No Similar Projects information available for 5R01AI158832-04